CCNB1 and cancer: Variations in the anti-mitotic activity and disruption of MT dynamics in numerous cancer cell types have been observed due to differences in the chemical carbocyclic structure of SLs, all of which trigger G2/M arrest via the upregulation of p-Cdk1 (Try 15) and cyclin B1 (Bosco & Golsteyn, 2017).